BACKGROUND: Recently, single nucleotide polymorphisms (SNPs) were identified in the promoter region of the perforin gene (PRF1) and it was found that the -398T mutant allele is correlated with lower amounts of protein in circulating CD8(+) cytotoxic T lymphocytes. OBJECTIVE: The aim of this study was to investigate the presence of the -398C/T polymorphism in the perforin gene in oncohematological patients. METHODS: Sixty-two patients with hematological malignancies treated at the teaching hospital of the Universidade Federal do Triângulo Mineiro were invited to participate in this study. The identification of the polymorphism was achieved by amplification using polymerase chain reaction, digestion using the TaqI enzyme and electrophoresis in 1% agarose gel. RESULTS: The heterozygous -398C/T polymorphism was identified in 16.7% patients with acute lymphoblastic leukemia, 40% with multiple myeloma, 50% with essential thrombocythemia, 14.3% with Hodgkin's disease, 7.7% with non-Hodgkin lymphoma and 33.3% with chronic lymphocytic leukemia. The homozygous mutant allele was identified in one mulatto individual (25%) with myelodysplastic syndrome. When Afro-Brazilian and Whites were analyzed together, there was a higher frequency of the -398T allele in patients than in healthy individuals (p-value = 0.0291). CONCLUSION: ne patient was homozygous for the -398T allele. Based on these findings, further studies should be conducted to assess whether the presence of this polymorphism may be a risk factor for the development of hematologic malignancies.
BACKGROUND: Recently, single nucleotide polymorphisms (SNPs) were identified in the promoter region of the perforin gene (PRF1) and it was found that the -398T mutant allele is correlated with lower amounts of protein in circulating CD8(+) cytotoxic T lymphocytes. OBJECTIVE: The aim of this study was to investigate the presence of the -398C/T polymorphism in the perforin gene in oncohematological patients. METHODS: Sixty-two patients with hematological malignancies treated at the teaching hospital of the Universidade Federal do Triângulo Mineiro were invited to participate in this study. The identification of the polymorphism was achieved by amplification using polymerase chain reaction, digestion using the TaqI enzyme and electrophoresis in 1% agarose gel. RESULTS: The heterozygous -398C/T polymorphism was identified in 16.7% patients with acute lymphoblastic leukemia, 40% with multiple myeloma, 50% with essential thrombocythemia, 14.3% with Hodgkin's disease, 7.7% with non-Hodgkin lymphoma and 33.3% with chronic lymphocytic leukemia. The homozygous mutant allele was identified in one mulatto individual (25%) with myelodysplastic syndrome. When Afro-Brazilian and Whites were analyzed together, there was a higher frequency of the -398T allele in patients than in healthy individuals (p-value = 0.0291). CONCLUSION: ne patient was homozygous for the -398T allele. Based on these findings, further studies should be conducted to assess whether the presence of this polymorphism may be a risk factor for the development of hematologic malignancies.
Entities:
Keywords:
Hematologic neoplasms; Perforin; Polymorphism, genetic; Polymorphism, single nucleotide
Authors: P Henkart; M Henkart; P Millard; P Frederikse; J Bluestone; R Blumenthal; C Yue; C Reynolds Journal: Adv Exp Med Biol Date: 1985 Impact factor: 2.622
Authors: S E Stepp; R Dufourcq-Lagelouse; F Le Deist; S Bhawan; S Certain; P A Mathew; J I Henter; M Bennett; A Fischer; G de Saint Basile; V Kumar Journal: Science Date: 1999-12-03 Impact factor: 47.728
Authors: Elena E Solomou; Federica Gibellini; Brian Stewart; Daniela Malide; Maria Berg; Valeria Visconte; Spencer Green; Richard Childs; Stephen J Chanock; Neal S Young Journal: Blood Date: 2007-02-20 Impact factor: 22.113
Authors: D McIlroy; L Meyer; Y Dudoit; A Samri; J-F Delfraissy; B Autran; P Debré; I Theodorou Journal: Int J Immunogenet Date: 2006-04 Impact factor: 1.466
Authors: C M Walsh; M Matloubian; C C Liu; R Ueda; C G Kurahara; J L Christensen; M T Huang; J D Young; R Ahmed; W R Clark Journal: Proc Natl Acad Sci U S A Date: 1994-11-08 Impact factor: 11.205
Authors: M E van den Broek; D Kägi; F Ossendorp; R Toes; S Vamvakas; W K Lutz; C J Melief; R M Zinkernagel; H Hengartner Journal: J Exp Med Date: 1996-11-01 Impact factor: 14.307